0001193125-26-117794
SEC filingQuince Therapeutics, Inc. received Nasdaq notices on March 16 and 17, 2026, for failing the Minimum Bid Price Requirement (below $1.00 for 30 consecutive business days) and MVLS Requirement (below $50,000,000 for 30 days). The Company has 180 calendar days until September 14, 2026, to regain compliance, with trading continuing uninterrupted on Nasdaq Global Select Market under QNCX.